-+ 0.00%
-+ 0.00%
-+ 0.00%
20/20 BioLabs Q3 net loss widens 67% year over year to $1.38 million; Q3 revenue falls 9% to $380,216
Share
Listen to the news
20/20 BioLabs Q3 net loss widens 67% year over year to $1.38 million; Q3 revenue falls 9% to $380,216
  • 20/20 BioLabs’ third-quarter 2026 net loss widened 67% year over year to $1.38 million.
  • Revenue fell 9% year over year to $380,216, reflecting the timing of state-funded firefighter cancer screening programs.
  • Cash totaled $3.63 million at September 30, 2026, with no outstanding borrowings.
  • Vermont executed a two-year firefighter screening contract, with testing expected to contribute revenue in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 20/20 Biolabs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161605PRIMZONEFULLFEED9878777) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending